Compare · JNJ vs PPCB
JNJ vs PPCB
Side-by-side comparison of Johnson & Johnson (JNJ) and Propanc Biopharma Inc. (PPCB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and PPCB operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $675.03B, about 355107.9x PPCB ($1.9M).
- JNJ has been more active in the news (16 items in the past 4 weeks vs 8 for PPCB).
- JNJ has more recent analyst coverage (25 ratings vs 0 for PPCB).
- Company
- Johnson & Johnson
- Propanc Biopharma Inc.
- Price
- -
- -
- Market cap
- $675.03B
- $1.9M
- 1M return
- +12.78%
- -
- 1Y return
- +44.19%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 16
- 8
- Recent ratings
- 25
- 0
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest JNJ
- Johnson & Johnson Announces CAPLYTA (lumateperone) Shows Significant and Rapid Improvement in Bipolar Mania in Second Pivotal Phase 3 Study
- Raised Outlooks and a Cancer Approval Arrive in the Middle of Medicare Open Enrollment
- Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide
- Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients
- FDA Approval for RYBREVANT FASPRO issued to JANSSEN BIOTECH
- Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer
- Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results
- Johnson & Johnson to Host Enterprise Business Review
- SEC Form 13F-HR filed by Johnson & Johnson
- RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer
Latest PPCB
- Propanc Biopharma Reports Preclinical Data with PRP & PRP plus TGF-β Inhibitor on TGF-β Pathway in Pancreatic Cancer
- Propanc Biopharma Advances Bioanalytical & Immunogenicity Assay Development for Phase 1b First-In-Human Study in up to 50 Advanced Cancer Patients
- SEC Form 8-K filed by Propanc Biopharma Inc.
- Propanc Biopharma Advances Clinical Development Preparation for PRP Phase 1b First-In-Human Study in Up to 50 Advanced Cancer Patients
- Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic Vulnerability
- CORRECTION -- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
- SEC Form DEF 14C filed by Propanc Biopharma Inc.
- Propanc Biopharma’s Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells
- Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer